Recent Assignments

---

Strategy Development - SPAC Target Search  |  Opportunity Assessment - New Market  
Opportunity Assessment - Revenue Forecast for Growth Business | Corporate Development - Strategic Acquisition

---

Strategy Development - SPAC Target Search

Issue: The partners of a healthcare-focused special purpose acquisition company (SPAC) needed to identify and qualify an attractive private company to acquire

• Approach: Scisive identified prospective candidates by searching its internal databases, conducting secondary market research, and drawing on its network in venture capital and private equity firms. Scisive developed short profiles of all acquisition candidates and presented them to the client, who selected the most attractive companies for further research. For the selected candidates, Scisive performed more in-depth due diligence and facilitated introductions to company management and Board members
• Solution: Scisive conducted three major rounds of search and identified 236 companies of interest, which encompassed every major medical product and service sector:

Industry Sector	Number of Companies
Pharmaceuticals	74
Biopharmaceuticals	35
Diagnostics	11
Medical devices and equipment	60
Services	50
Others	6
Total	236

Scisive assessed a broad array of markets for the candidate companies:

Therapeutic Area/Market	Number of Companies
Allergy	2
Anesthesia, pain, & acute care	9
Anti-infectives	7
Cardiology & vascular	28
Dentistry	2
Dermatology	8
Diabetes	11
Diagnostics, including genetic testing	11
Drug delivery	6
Gastrointestinal	6
Healthcare providers, including home healthcare services	15
Imaging	5
Immunology/autoimmune disorders	6
Infectious disease	4
Nephrology & urology	5
Neurology	8
Oncology/hematology	29
Ophthalmology	7
Organ transplantation	4
Orthopedics	6
Services for healthcare providers	8
Wound healing/care	3
Others	37
Total	236

Over the course of the project, Scisive developed profiles of all 236 companies and performed more in-depth due diligence on 107 companies.

• Resolution: The SPAC signed letters of intent with four companies.

 

---

Opportunity Assessment - New Market

Issue: European pharmaceutical firm had a promising drug in development for a new therapeutic area in which they did not have a market presence. The client wanted to assess the attractiveness of the new market and prescribing medical specialty. The Board needed to decide on resources for drug development, and whether to enter the new market on its own or partner out the drug.

• Approach: Scisive developed an in-depth disease map of conditions treated by the specialty, including unmet needs and sales of current drugs. Scisive also assessed the competitive landscape and profiled the major players.
• Solution: Scisive first presented the senior management with the current market landscape and a strategic pathway for them to enter and develop a new franchise. Scisive then assisted management in presentation to the Board.
• Resolution: The Board approved moving forward with drug development, which the company is pursuing.

 

---

Opportunity Assessment - Revenue Forecast for Growth Business

Issue: A private biotechnology company had developed a thriving drug screening services business. The client needed a third-party assessment of its growth prospects to assist in alliance discussions, as a current revenue-based valuation would significantly undervalue the business.

• Approach: Scisive developed a bottom-up revenue model and forecast five years in the future, based on the number of customers and project sizes. The model was based on extensive and highly sophisticated primary and secondary market research with current and potential customers, academic researchers, and industry experts.
• Solution: Scisive presented the model to company management, with detailed documentation regarding the current market and future projections. The model design was user-friendly to allow the client and prospective allies to do sensitivity analysis.
• Resolution: The company utilized the Scisive report in sales negotiations, as Scisive's projections were similar to the company's, which had not been disclosed during the project.

---

Corporate Development - Strategic Acquisition

Issue: Biotechnology company with cutting-edge technology and preclinical product portfolio faced fund-raising challenge. Senior management wanted to explore acceleration of commercialization via a strategic acquisition.

• Approach: Scisive led a series of interactive workshops with the management team to identify areas of therapeutic and technical interest, review, and prioritize acquisition candidates.
• Solution: Scisive identified 100 acquisition candidates that met the search criteria; during the workshop, the client determined 20 were worth pursuing. Scisive then contacted all 20 candidates to determine their level of interest, and recommended pursuit of 8 companies.
• Resolution: Board and management decided to continue independent course and to consider product acquisitions.